The Role of Calcineurin Inhibitors in Lupus Nephritis In the U.S, lupus nephritis affects approximately 40–50% of patients with systemic lupus erythematosus (SLE), contributing significantly to the morbidity and mortality of the affected individuals (1). However, significant https://t.co/sc4cgAYzGy

Rheumatic Immune-related Adverse Effects with Checkpoint Inhibitor Therapy A retrospective study of patients who developed rheumatic immune-related adverse events (R-irAEs) after receiving immune checkpoint inhibitors (ICIs) at two oncology centers in Spain suggests that early https://t.co/jKCbIvfebm

Sodium-glucose cotransporter-2 (SGLT2) inhibitors lower serum uric acid levels, by approximately 0.6 to 1.5 mg/dL. They increase renal uric acid excretion via a uricosuric effect), thereby reducing gout risk by 30% to 50%. https://t.co/weXVOhpiP9 https://t.co/NsCRNi9JI9

Metanalysis of calcineurin inhib. in RA - 11 RCTs, 1793 RA pts. Cyclosporin (CSA( (RR 1.6 & Tacrolimus (TAC (RR 2.1) signif improved ACR20 responses. CSA was dose dependent, less so w/ TAC. Both require serum Creat. monitoring consistent increase in s-Cr https://t.co/OxNGYbupnt https://t.co/F08vDCMYtr

2 RCTs of 699 children Tx in ER for acute limb injury compared 1 dose of oral acetaminophen or hydromorphone to ibuprofen - none significantly reduce self-reported pain scores at 60 minutes. Use of hydromorphone resulted in a 4-fold increase in adverse events. https://t.co/cqddDES9V0

American Academy of Physician Associates is determined to change PA to mean 'physician associate' in USA. Maine, New Hampshire, Oregon have adopted it, but the AMA is opposed. This has become a legislative, financial and legal issue. https://t.co/u0tejo0lvn https://t.co/1VEbwpqlN8

NEJM: Obinutuzumab in Active Systemic Lupus Erythematosus A phase 3 trial of obinutuzumab, an anti-CD20 monoclonal antibody, showed potent B-cell depletion and clinical efficacy active systemic lupus erythematosus without evidence of nephritis. https://t.co/b5qHBotxbI https://t.co/dqzZodOokq

Data from the KEEPsAKE 1 trial in bio-naive patients with PsA Dr. Wells and Dr. Singla share 5-year safety and efficacy data of an IL–23 inhibitor and their thoughts on using it to manage PsA. Sponsored by AbbVie Medical Affairs + Health Impact.  https://t.co/xoPdYAof7m https://t.co/ycqMod2qLN

Prebiotic fibre improves knee OA. Study of 117 older adults w/ KOA Rx w/ 6wks of inulin (fibre) or Physiotherapy exercise (PSE) or both vs PBO. Both Inulin & PSE signif improved pain & PSE vs PBO ( −1.11 to -2.5; p <0.045); inulin also improved pain sensitivity & grip strength https://t.co/Efic4mru1i

Long-Term Hydroxychloroquine Retinopathy Risk About one in 18 patients taking hydroxychloroquine (HCQ) for 15 years develop retinal damage, a new meta-analysis indicated. https://t.co/Gp6o0FfEYA https://t.co/TjLNXl229v

AI model was superior in diagnosing Acromegaly from dorsal hand photographs - w. sensitivity 0.89, specificity 0.91, PPV 0.88, NPV 0.93, F1-score of 0.89, AUC 0.96, outperforming specialists, Study of 716 pts (317 acromegaly; 399 controls) & 11480 images, from 15 Japanese https://t.co/8RM4wf8vGi

Basic, full-read overview of "JAK inhibitors: risks and safety principles" from the Pharmaceutical Journal. Addresses MOA, indications, warnings, monitoring, adverse effects, interactions, Serious AEs, vaccination and best practices. https://t.co/qrqeu1CzRg https://t.co/7qIszLwUrf